Sentences with phrase «leading cancer research centers»

Not exact matches

Over the years, Roswell Park has also become recognized as one of the United States» leading cancer treatment and research centers, and it recruits physicians and researchers from across the world to come live and work in the Buffalo area.

Dr. Greenbaum and Dr. Łksza also played an integral role in a companion piece of research led by researchers Vinod P. Balachandran, MD, Taha Merghoub, PhD, and Steven D. Leach, MD, at Memorial Sloan Kettering Cancer Center (MSK) that was also published in Nature today.

«Our findings suggest that teens and young adults who seek indoor tanning may be especially vulnerable to developing BCC, the most common form of skin cancer, at a young age,» said lead author Professor Margaret Karagas, co-director of the Cancer Epidemiology and Chemopreventon Research Program at the Norris Cotton Cancer Center and Director of the Children's Environmental Health and Disease Prevention Research Center at Dartcancer, at a young age,» said lead author Professor Margaret Karagas, co-director of the Cancer Epidemiology and Chemopreventon Research Program at the Norris Cotton Cancer Center and Director of the Children's Environmental Health and Disease Prevention Research Center at DartCancer Epidemiology and Chemopreventon Research Program at the Norris Cotton Cancer Center and Director of the Children's Environmental Health and Disease Prevention Research Center at DartCancer Center and Director of the Children's Environmental Health and Disease Prevention Research Center at Dartmouth.

This is the main finding of new research led by investigators at NYU Langone Medical Center and its Perlmutter Cancer Center and published online May 19 in the Journal of the National Cancer Institute.

New findings from an international research team led by University of North Carolina Lineberger Comprehensive Cancer Center scientists may improve detection of skin cancer that lacks any brown or black Cancer Center scientists may improve detection of skin cancer that lacks any brown or black cancer that lacks any brown or black color.

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

Appearing alongside the heads of five of NIH's 27 institutes and centers, Collins instead offered examples of how NIH research has led to new drugs for cystic fibrosis and cancer treatments that help the immune system fight tumors.

An experimental drug in early development for aggressive brain tumors can cross the blood - brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

SWOG biostatistician Joseph Unger, Ph.D., of Fred Hutchinson Cancer Research Center, led the work and will present it on a June 5 ASCO panel.

The first author of the Science paper is Laura Gaydos, a graduate student in Strome's lab at UC Santa Cruz who led the study for her Ph.D. thesis and is now a postdoctoral researcher at Fred Hutchinson Cancer Research Center in Seattle.

Tse's research team included Drs. Shotaro Hagiwara, the lead author and chief of hematology, and Sohtaro Mine of the National Center for Global Health and Medicine in Tokyo, Ana - Iris Schiefer of the Medical University of Vienna and Lukas Kenner of the Ludwig Boltzmann Institute for Cancer Research and Medical University ofresearch team included Drs. Shotaro Hagiwara, the lead author and chief of hematology, and Sohtaro Mine of the National Center for Global Health and Medicine in Tokyo, Ana - Iris Schiefer of the Medical University of Vienna and Lukas Kenner of the Ludwig Boltzmann Institute for Cancer Research and Medical University ofResearch and Medical University of Vienna.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

A study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified an abnormal metabolic pathway that drives cancer - cell growth in a particular glioblastoma suCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified an abnormal metabolic pathway that drives cancer - cell growth in a particular glioblastoma suCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified an abnormal metabolic pathway that drives cancer - cell growth in a particular glioblastoma sucancer - cell growth in a particular glioblastoma subtype.

«The phi test helps physicians distinguish prostate cancer from benign conditions by utilizing three different PSA markers (PSA, freePSA and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels,» said Kevin Slawin, MD, director, Vanguard Urologic Institute at Memorial Hermann Medical Group, clinical professor of Urology at Baylor College of Medicine and director of Urology, Memorial Hermann Hospital ‐ Texas Medical Center, who performed some of the key research that led to the development of the phi test and who also began using the test in February.

Dr. David Fredricks, a physician - scientist at Fred Hutchinson Cancer Research Center and senior author of the study, said the results could lead to a better understanding of how biological conditions may promote infection by the virus that causes AIDS, and perhaps offer targets for future prevention rResearch Center and senior author of the study, said the results could lead to a better understanding of how biological conditions may promote infection by the virus that causes AIDS, and perhaps offer targets for future prevention researchresearch.

A new study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) reveals details about how such viral DNA insertion complexes hunt for a suitable spot and how quickly insertion happens at the chosen site.

This makes the development of an effective vaccine to protect against infection, as well as antiviral therapy to combat already - existing infections, particularly challenging,» says Dr. Grant Hansman, a virologist who leads the CHS Research Group on Noroviruses at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University.

Other main contributors include Thomas Milner, professor of biomedical engineering in UT Austin's Cockrell School of Engineering and his lab members; Jialing Zhang, research associate at the Eberlin Lab at UT Austin who led the experimental work with other lab members; Anna Sorace, assistant professor at UT Austin's Dell Medical School; Chandandeep Nagi and Wendong Yu, professors of pathology at Baylor College of Medicine, and Jinsong Liu, professor of pathology at University of Texas MD Anderson Cancer Center.

A neuro - oncology research team at Dartmouth's Norris Cotton Cancer Center, led by the Director Mark A. Israel, MD with first author Gilbert J. Rahme, PhD, recently identified the transcription factor Id4 as a suppressor of tumor cell invasion in glioblastoma.

Summers and the research team, led by Dr. Mike Jensen at the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroyresearch team, led by Dr. Mike Jensen at the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroy cCancer Research at Seattle Children's Research Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroyResearch at Seattle Children's Research Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroyResearch Institute, are opening PLAT - 04 after discovering that of the patients who relapsed in the PLAT - 02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroy cancercancer.

«The connection between inflammation and cancer has moved to center stage in the research arena,» notes Robert A. Weinberg of the Massachusetts Institute of Technology's Whitehead Institute for Biomedical Research, who has highlighted the changing emphasis in a revision of his leading textbook, The Biology of Cancer (Garland Science, cancer has moved to center stage in the research arena,» notes Robert A. Weinberg of the Massachusetts Institute of Technology's Whitehead Institute for Biomedical Research, who has highlighted the changing emphasis in a revision of his leading textbook, The Biology of Cancer (Garland Scienceresearch arena,» notes Robert A. Weinberg of the Massachusetts Institute of Technology's Whitehead Institute for Biomedical Research, who has highlighted the changing emphasis in a revision of his leading textbook, The Biology of Cancer (Garland ScienceResearch, who has highlighted the changing emphasis in a revision of his leading textbook, The Biology of Cancer (Garland Science, Cancer (Garland Science, 2006).

So a team led by autoimmunity researcher and rheumatologist J. Lee Nelson of the Fred Hutchinson Cancer Research Center in Seattle, Washington, took samples from autopsied brains of 59 women who died between the ages of 32 and 101.

Jean - Pierre Issa, MD, Director of the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine and co-Leader of the Cancer Epigenetics Program at the Fox Chase Cancer Center is lead author of the study, which has been published August 19 in the journal, Lancet Oncology.

Now, a new study led by infectious disease researcher Dr. Sachiko Seo, formerly of Fred Hutch and now a physician at the National Cancer Research Center East in Chiba, Japan, and Boeckh and published last month in the journal Haematologica has found that like more «serious» viruses, rhinovirus can cause pneumonia — and when it does, it can be deadly to those recovering from transplantation.

The preclinical study was led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

Jeroen Roelofs, assistant professor in the Division of Biology and a research affiliate with the university's Johnson Cancer Research Center, led a study on a specific step in the assembly of protresearch affiliate with the university's Johnson Cancer Research Center, led a study on a specific step in the assembly of protResearch Center, led a study on a specific step in the assembly of proteasomes.

Moffitt Cancer Center, a leader in molecular cancer research, and a research team led by Jia Fang, Ph.D., assistant member of the Tumor Biology Department, has discovered a new way to control the activity of SETDB1, a protein that is often upregulated in cCancer Center, a leader in molecular cancer research, and a research team led by Jia Fang, Ph.D., assistant member of the Tumor Biology Department, has discovered a new way to control the activity of SETDB1, a protein that is often upregulated in ccancer research, and a research team led by Jia Fang, Ph.D., assistant member of the Tumor Biology Department, has discovered a new way to control the activity of SETDB1, a protein that is often upregulated in cancercancer.

Genetically analysing lesions in the food pipe could provide an early and accurate test for esophageal cancer, according to research led by Queen Mary University of London (QMUL), Academic Medical Center in Amsterdam and Arizona State University.

In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutacancer patients with B - raf mutations.

«We challenged a current dogma in the field that emphasized PLK1's role in mitosis (cell division) as a primary mechanism for cancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Medcancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of MedCancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of MedCancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Medicine.

The article was co-authored by leaders in HIV vaccinology, including Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and lead author Lawrence Corey, M.D., of the Fred Hutchinson Cancer Research Center.

«Even before the patient completes all of the MRIs, CT scans and other imaging procedures following diagnosis, we can have a recommendation for which drug and dosage to prescribe,» said Kareem Azab, PhD, an assistant professor of radiation oncology at the School of Medicine and the Siteman Cancer Center member who leads the research.

Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Instcancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer InstCancer Center The research is published online in the Journal of the National Cancer InstCancer Institute.

The study, published in PLOS Medicine, was led by Wei Zheng, M.D., Ph.D., MPH, professor of Medicine and director of the Vanderbilt Epidemiology Center, and John Potter, M.D., Ph.D., a member and scientific advisor of the Fred Hutchinson Cancer Research Center, Seattle, Washington.

The researchers, led by Professor Bernd Pichler at the Werner Siemens Imaging Center, worked with dermatologists, pathologists and immunologists at the University hospitals and at the German Consortium for Translational Cancer Research.

The achievement, say researchers at Georgetown University Medical Center who led the research, represents a critical advance in the effort to understand the origin and drivers of this puzzling cancer — the most common in men.

The research team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancerresearch team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson CancerResearch in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.

The study was led by Guoping Fan, professor of human genetics and molecular biology and member of both the Jonsson Comprehensive Cancer Center and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

Young people across the United States who smoke electronic cigarettes are considerably more likely to start smoking traditional cigarettes within a year than their peers who do not smoke e-cigarettes, according to an analysis led by the University of Pittsburgh Center for Research on Media, Technology, and Health (CRMTH) and the Dartmouth - Hitchcock Norris Cotton Cancer Center.

The second report, identifies the immunotherapy resistance mechanism in melanoma cells, is from a group led by Kai Wucherpfennig, MD, PhD, director of Dana - Farber's Center for Cancer Immunotherapy Research, and Shirley Liu, PhD, of Dana - Farber.

A Canadian team, led by Marco Marra of the British Columbia Cancer Research Center in Vancouver, worked to completely sequence a strain of the virus isolated from a patient who died of SARS in Toronto.

The study was led by Dr. Leslie Kean, Associate Director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute.

A multi-center study led by Fred Hutchinson Cancer Research Center has found that high - dose supplementation with both the trace element selenium and vitamin E increase the risk of high - grade prostate cCancer Research Center has found that high - dose supplementation with both the trace element selenium and vitamin E increase the risk of high - grade prostate cancercancer.

«We already know that coordinated, patient - centered palliative care improves care quality, enhances survival, and reduces costs for persons with cancer,» said R. Sean Morrison, MD, Director of the National Palliative Care Research Center and Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai and lead author of the study.

Cosette Wheeler, PhD, at The University of New Mexico Comprehensive Cancer Center, led the research team and the efforts of the New Mexico Human Papillomavirus Pap Registry, the data source used in the study.

The altered metabolism of two essential amino acids helps drive the development of the most common and lethal form of brain cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — Jcancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — JCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — JCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

A new study led by scientists at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) suggests that dopamine — an inexpensive drug currently used to treat heart, vascular and kidney disorders — can be safely used in cancer treatment to curb the growth of blood vessels in tCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) suggests that dopamine — an inexpensive drug currently used to treat heart, vascular and kidney disorders — can be safely used in cancer treatment to curb the growth of blood vessels in tCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) suggests that dopamine — an inexpensive drug currently used to treat heart, vascular and kidney disorders — can be safely used in cancer treatment to curb the growth of blood vessels in tcancer treatment to curb the growth of blood vessels in tumors.

Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer Ccancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer CCancer Center.

Now a research team led by investigators in the Cancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breastresearch team led by investigators in the Cancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breast cCancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breastResearch Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breast cancercancer.

In addition to lead author Dr. Brent Sutherland, of the Hutchinson Center, contributing research also came from scientists at Baylor College of Medicine in Houston, Texas; the Center for Cancer and Stem Cell Biology at Texas A&M University; and the Institut National de la Sante et de la Recherche Medicale in Paris, France.